BRCA2 and ovarian carcinoma: The BRCA1 and BRCA2 tumor suppressor genes are critical for the HRR of DNA double‐strand breaks by the HRR pathway; therefore, BRCA1/BRCA2‐mutated ovarian cancers are usually more sensitive to cisplatin.201